Month: March 2020

NEW ALBANY, Ohio, March 15, 2020 (GLOBE NEWSWIRE) — Abercrombie & Fitch Co. (NYSE: ANF) today announced updates to its global store operations in response to the continued spread of COVID-19. With the wellbeing of its customers, associates and communities in mind, and to help limit the spread of the virus, Abercrombie & Fitch Co. will temporarily close all stores across its brands outside of the APAC region, effective March 15 in North America and March 16 in EMEA, until March 28, 2020.  Its locations in the APAC region will remain open. The Company’s online stores currently remain open in all regions.Due to the heightened uncertainty relating to the potential impacts of COVID-19 on the Company’s business operations, including its duration and its impact on overall demand for merchandise, the Company is withdrawing the...

Í 11. viku 2020 keypti Festi alls 2.157.876 hluti eins og hér segir:Er um að ræða tilkynningu um kaup Festi á eigin bréfum í samræmi við endurkaupaáætlun sem var tilkynnt um 2. mars 2020 í tilkynningu til Nasdaq OMX Iceland.Fyrir kaupin átti Festi 3.157.876 hluti eða 0,96% af útgefnu hlutafé. Festi á í dag 4.315.752 hluti sem samsvarar 1,31% af hlutafé félagsins. Endurkaupin munu að hámarki nema 5.000.000 hlutum eða 1,5% af útgefnum hlutum í félaginu. Áætlunin er í gildi til 23. mars 2020, eða fram að aðalfundi félagsins 2020.Framkvæmd endurkaupaáætlunarinnar er í samræmi við VIII. kafla laga um hlutafélög nr. 2/1995 og viðauka II við reglugerð um innherjaupplýsingar og markaðssvik nr. 630/2005.Nánari upplýsingar veitir Eggert Þór Kristófersson, forstjóri Festi hf., (eggert@festi.is)

Buy-back of shares in Festi amounted to 2.157.876 shares in week 11 2020:This announcement of purchase of own shares is in accordance with Festi‘s buy-back programme announced by notice to Nasdaq OMX Iceland on 2 March 2020.  Prior to the transactions Festi held 3,157,876 of own shares or 0,96% and holds 4,315,752 shares or 1,31% of own shares after the transactions. The maximum of the buy-back is 5,000,000 shares or 1,5% of issued shares. The buy-back programme is in force until 23 March 2020 which is the date for the Annual General Meeting of the company.The buy-back programme is carried out in accordance with Chapter VIII of the Act on limited liability companies No. 2/1995 and Annex II to the Regulation on insider information and market abuse No. 630/2005.For further information contact Eggert Þór Kristófersson, CEO of Festi hf.,...

Company announcement no 2020-05                              15 March 2020Coronavirus expected to have substantial, short-term negative impact on hearing healthcare marketMaintain expectation to generate organic sales growth significantly above market growth rate in 2020Outlook for 2020 withdrawn due to uncertainty of impact of current outbreak of coronavirus diseaseAs a result of the current global outbreak of coronavirus, we expect to see a substantial, short-term negative impact on demand in the hearing healthcare market. This is a consequence of the recent increase in the spread of coronavirus in several large markets where people – particularly the elderly population – are advised and choose to stay at home to limit the spread of coronavirus. We believe the negative impact will be temporary and lead to pent-up demand, which will materialise...

Selskabsmeddelelse nr. 2020-05                                             15. marts 2020Coronavirus forventes at få betydelig, kortsigtet negativ effekt på høresundhedsmarkedetFastholder forventning om organisk salgsvækst betydeligt over markedsvækstraten i 2020Forventninger til 2020 trækkes tilbage pga. usikkerhed om effekten af det aktuelle coronavirus-udbrudPå grund af det aktuelle globale udbrud af coronavirus forventer vi at se en betydelig, kortsigtet negativ effekt på efterspørgslen på høresundhedsmarkedet. Dette er en konsekvens af den seneste stigning i spredningen af coronavirus på adskillige store markeder, hvor folk – især den ældre del af befolkningen – rådes til og vælger at blive hjemme for at begrænse spredningen af coronavirus. Vi mener, at den negative effekt vil være midlertidig og medføre en ophobning i efterspørgslen,...

PHILADELPHIA, March 14, 2020 (GLOBE NEWSWIRE) — Urban Outfitters, Inc. (NASDAQ:URBN), a leading lifestyle products and services company which operates a portfolio of global consumer brands comprised of Anthropologie, BHLDN, Free People, Terrain, Urban Outfitters and Nuuly brands and the Food and Beverage division provides an update on COVID-19.The global spread of COVID-19 is affecting every one of us.  The safety and health of our communities, including our loyal customers and dedicated associates, is always of the utmost importance to us.As far as we know, none of our employees have tested positive for COVID-19.  In an effort to protect our communities, we have decided to close all of our stores around the globe.  Stores will not reopen until at least March 28. We will continue to pay our store teams during this time. We will...

The Annual General Meeting of Arion Bank will be held at the Bank’s headquarters at Borgartún 19, 105 Reykjavík on 17 March 2020 at 16:00.One item on the agenda is the election of the Board of Directors. Deadline for notifications of candidacy was at 16:00 on 12 March 2020.All current board members have announced that they intend to stand for re-election. The Nomination Committee has examined the nominations received and has assessed whether the candidates are dependent or independent of the Bank. The Nomination Committee’s report and information on the candidates are attached. The following candidates have announced that they wish to stand for election to the Board of Directors of Arion Bank and the Nomination Committee proposes that they be elected to the Bank’s Board of Directors.Brynjólfur BjarnasonHerdís Dröfn FjeldstedGunnar SturlusonLiv...

Aðalfundur Arion banka, verður haldinn í höfuðstöðvum bankans að Borgartúni 19, 105 Reykjavík, þann 17. mars. 2020, kl. 16:00Á dagskrá fundarins er m.a. kosning stjórnar bankans. Frestur til að skila inn framboðum til stjórnar rann út 12. mars 2020, kl. 16:00.Allir núverandi stjórnarmenn hafa boðið sig fram til áframhaldandi setu í stjórn bankans. Tilnefningarnefnd hefur farið yfir þau framboð sem bárust og metið hæði frambjóðenda. Skýrsla tilnefningarnefndar og upplýsingar um frambjóðendur er meðfylgjandi. Eftirtaldir aðilar eru í framboði til stjórnar Arion banka og leggur tilnefningarnefnd til að þeir verði kjörnir í stjórn bankans:Brynjólfur BjarnasonHerdís Dröfn FjeldstedGunnar SturlusonLiv FiksdahlPaul Richard HornerRenier LemmensSteinunn Kristín ÞórðardóttirVaramenn:Ólafur Örn SvanssonSigurbjörg Ásta JónsdóttirÞröstur RíkharðssonTilnefningarnefnd...

Aðalfundur Vátryggingafélags Íslands hf. verður haldinn fimmtudaginn 19. mars 2020 kl. 16:00 í höfuðstöðvum félagsins, Ármúla 3, 108 Reykjavík. Athygli er vakin á því að jafnframt er gefinn kostur á rafrænni fjarþátttöku á fundinum. Framboðsfrestur vegna stjórnar og tilnefningarnefndar Vátryggingafélag Íslands hf. rann út þann 14. mars 2020 kl. 16:00.Meðfylgjandi eru upplýsingar um þá aðila sem gefið hafa kost á sér til setu í stjórn og varstjórn annarsvegar, og í tilnefninganefnd hins vegar.Er það mat stjórnar að öll framboð séu gild sbr. 63. gr. a. hlutafélagalaga nr. 2/1995. Þar sem þrír einstaklingar hafa boðið sig fram til setu í tilnefningarnefnd er ljóst að sjálfkjörið er í nefndina.Önnur fundargögn tengd hluthafafundi má nálgast á vef félagsins: https://vis.is/vis/fjarfestar/hluthafafundur/                                                                                                                ...

紐約州水牛城, March 14, 2020 (GLOBE NEWSWIRE) — Athenex, Inc. (NASDAQ: ATNX) 是一家致力於研究、開發和商業化治療癌症和相關疾病新療法的的全球生物製藥公司。公司今天就最近宣佈的冠狀病毒爆發大流行公佈公司的營運最新資訊。Athenex 的營運計劃仍將繼續按計劃展開，並且公司目前的評估是，口服紫杉醇的 NDA 申請以及口服紫杉醇和 Tirbanibulin 軟膏的上市前準備不受影響。此外，公司與美國 FDA 和其他監管機構的互動交流目前仍然按計劃進行。儘管 Athenex 在重慶的中國業務受到冠狀病毒情況影響，但公司欣然報告，根據當地政府的建議，此類業務運作已於今年 3 月第一週恢復正常。公司的泰濠工廠將繼續生產用於臨床和註冊需求的 API，新的 API 工廠的建造工程繼續按計劃施工。Athenex 將全球員工的福祉放在首位，並認真遵守相關地方當局關於預防措施的建議，包括有關出差、在家工作和限制參加大型聚會的政策。公司將繼續成為全球公民，並將緊密合作以支持全球各公共衛生當局，並將繼續監視不斷變化的情況。關於  Athenex, Inc. 創於 2003 年， Athenex, Inc.  是一家臨床階段的國際生物製藥公司，並致力成為研究、開發及商業化新一代癌症治療藥物的領導者。Athenex 下設三個平台，分別為腫瘤創新平台、商業平台和全球供應鏈平台。公司現有的臨床產品系列源自四個不同平台的科技：(1) 以 p-糖蛋白抑制劑為基礎的 Orascovery；(2) Src 酶抑制劑；(3) 受體工程化 T 細胞 (TCR-T) 及 (4) 精氨酸消除療法。Athenex 的員工遍佈全球，致力透過開發更有效及耐受的治療來改善癌症病人的生活。Athenex 在紐約水牛城以及克拉倫斯、新澤西州克蘭福德、德薩斯州休斯敦、伊利諾伊州芝加哥、香港、台灣台北、中國重慶、英國曼徹斯特、危地馬拉危地馬拉城、阿根廷布宜諾斯艾利斯等多個地方設有辦事處。如欲了解更多資訊，請瀏覽 www.athenex.com。前瞻性陳述...